UBIMAIOR 14CPS 50MG

UBIMAIOR 50 MG CAPSUDE

active ingredients

One capsule contains: Active ingredient: Ubidecarenone 50 mg. Excipient with known effect: lactose. For the full list of excipients, see paragraph 6.1.

Excellent

Lactose, polyvinylpyrrolidone insoluble, polyvinylpyrrolidone, Talco, colloidal silica moisturize, laurilsulfate sodium, magnesium stearate, Eritrosina E 127, Iron oxide E 172, Titanium dioxide E 171, Gelatina.

Therapeutic indications

Congenital deficit of coenzyme Q10.

Contraindications

Individual hypersensitivity already established towards the preparation.

Population

UBIMAIOR 50 mg capsules: one capsule per day, except for different prescription.

Conservation

Store the medicine in the original container to keep it safe from the light.

Warnings

Keep the medicine out of sight and reach of children. Important warnings about some excipients Ubimaior contains lactose: This medicine contains lactose, so patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose- galactose mal absorption, should not take this medicine.

Interactions

Not known.

Effects

Adverse events are listed below with classification for systems and organs according to MedDRA and frequency. The frequencies are defined as follows: very common (≥1/10), common (≥1/100, Classification for systems and organs Undesirable effects Disorders of metabolism and nutrition Reduced appetite Gastrointestinal diseases Disorders of gastric function, nausea, diarrhea Pathologies of skin and subcutaneous tissue Skin rash UBIMAIOR is usually well tolerated. In case of appearance of the undesirable effects mentioned above, stop treatment and consult the attending physician. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

In literature, cases of hyperdose were not described.

Although the theological studies conducted with UBIMAIOR animals have not shown any teratogenic effect, however, as for other drugs, its administration during the first three months of pregnancy should only be carried out in case of actual need under the direct control of the doctor.

Source: Farmadati